AIM 1W Final Edit Wave (4) (A)(B)(C) CorrectiveTest
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The A
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−24.80 USD
−17.32 M USD
170.00 K USD
641.92 K
About AIM ImmunoTech Inc.
Sector
Industry
CEO
Thomas Kenwood Equels
Website
Headquarters
Ocala
Founded
1966
FIGI
BBG000JL6Z80
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Related stocks
AIM AIM
post covid therapy treatment
Big Market value potential
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease cau
AIM Aim Immuno - Top pick for at least 500% plus gain Based on recent data and the indications , safety data (already used in humans) and a need by various communities such as people afflicted with ME this should be the number one meme stock for getting people help while sticking it to the naked shorts. Insiders buying and with indications and data i
AIM; Small Chart Analysis, Possible Cup and Handle formingDISCLAIMER
This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. There is absolutely no financial advice here because the only financial advice I can give is to research, research, and research. The purpose of this analysis is to serve as an e
AIM for the Sky*! Mileage may vary.Hello, take a seat and enjoy my basic analysis of AIM. I am not an analyst, of finances or anything else, just a dude saying friendly dude things. I could be the dude that everyone is friends with at the office, or I could be your crazy QAnon neighbour with a Ron Paul sign out front. Please do not t
$AIM: Potential 35-55% upside from today's closesee easy and self explanatory boxes on chart for Entry, Exit and Stop loss zones. Never chase any stock.
Not for any recommendation, Just an Idea. Like it >> Click 👍/comment, and follow.
Last week closed 3 trades from previous posts ( HX +65% in 83 days; CYRN +29% in 36 days; SPCB +80 in 31 days)
AIM: Greatest thing since sliced bread 🍞🔪Peaks are getting lower while troughs are getting higher in the duration of 5 days. You won't get a more obvious pennant than this.
Now what makes this pennant bullish ?
Well if we look at the Weekly log scale, we can see a clear case of a cup and handle, and we're almost done with the handle :)
granted EU Orphan Drug Designation for RintatolimodJUST GOT POSITIVE EU RECOMMENDATION
$AIM (old $HEB) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe.
Rintatolimod is Ampligen
This is going to trap shorts and when they PR this is going to explode!
www.ema.europa.eu
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AIM is 9.18 USD — it hasn't changed in the past 24 hours. Watch AIM ImmunoTech Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange AIM ImmunoTech Inc. stocks are traded under the ticker AIM.
AIM stock has fallen by −0.34% compared to the previous week, the month change is a 24.65% rise, over the last year AIM ImmunoTech Inc. has showed a −74.87% decrease.
We've gathered analysts' opinions on AIM ImmunoTech Inc. future price: according to them, AIM price has a max estimate of 150.00 USD and a min estimate of 150.00 USD. Watch AIM chart and read a more detailed AIM ImmunoTech Inc. stock forecast: see what analysts think of AIM ImmunoTech Inc. and suggest that you do with its stocks.
AIM stock is 3.60% volatile and has beta coefficient of 0.85. Track AIM ImmunoTech Inc. stock price on the chart and check out the list of the most volatile stocks — is AIM ImmunoTech Inc. there?
Today AIM ImmunoTech Inc. has the market capitalization of 6.76 M, it has decreased by −3.05% over the last week.
Yes, you can track AIM ImmunoTech Inc. financials in yearly and quarterly reports right on TradingView.
AIM ImmunoTech Inc. is going to release the next earnings report on Aug 19, 2025. Keep track of upcoming events with our Earnings Calendar.
AIM earnings for the last quarter are −8.00 USD per share, whereas the estimation was −8.00 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −8.00 USD per share. See more details about AIM ImmunoTech Inc. earnings.
AIM ImmunoTech Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach 100.00 K USD.
AIM net income for the last quarter is −3.71 M USD, while the quarter before that showed −5.97 M USD of net income which accounts for 37.91% change. Track more AIM ImmunoTech Inc. financial stats to get the full picture.
No, AIM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 8, 2025, the company has 23 employees. See our rating of the largest employees — is AIM ImmunoTech Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AIM ImmunoTech Inc. EBITDA is −17.07 M USD, and current EBITDA margin is −11.46 K%. See more stats in AIM ImmunoTech Inc. financial statements.
Like other stocks, AIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AIM ImmunoTech Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AIM ImmunoTech Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AIM ImmunoTech Inc. stock shows the sell signal. See more of AIM ImmunoTech Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.